Table 1 Clinicopathologic and molecular features of the 44 cancer cases analyzed.
From: SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma
Case # | Age | Gender | Diagnosis | ALT | SMARCAL1 IHC | ATRX IHC | IDH1 IHC |
|---|---|---|---|---|---|---|---|
1 | 34 | F | Giant cell GBM | ALT | Loss | Retained | Negative |
2 | 41 | M | Giant cell GBM | ALT | Loss | Retained | Negative |
3 | 36 | F | Giant cell GBM | ALT | Mis-localized | Retained | Negative |
4 | 59 | M | Giant cell GBM | ALT | Retained | Retained | Negative |
5 | 13 | F | Giant cell GBM | ALT | Retained | Retained | Negative |
6 | 45 | F | Giant cell GBM | ALT | Retained | Loss | Negative |
7 | 56 | F | Giant cell GBM | ALT | Retained | Loss | Negative |
8 | 17 | M | Giant cell GBM | ALT | Retained | Loss | Positive |
9 | 32 | M | Giant cell GBM | Negative | Retained | Retained | Negative |
10 | 4 | M | Giant cell GBM | Negative | Retained | Retained | Negative |
11 | 73 | M | Giant cell GBM | Negative | Retained | N/A | Negative |
12 | 67 | F | Giant cell GBM | Negative | Retained | Retained | Negative |
13 | 36 | F | Giant cell GBM | Negative | Retained | Retained | Negative |
14 | 53 | F | Giant cell GBM | Negative | Retained | Retained | Negative |
15 | 57 | M | Giant cell GBM | Negative | Retained | Retained | Negative |
16 | 58 | M | GBM with giant cell features | ALT | Loss | Retained | Negative |
17 | 57 | M | GBM with giant cell features | ALT | Retained | Retained | Negative |
18 | 38 | M | GBM with giant cell features | ALT | Retained | Retained | Negative |
19 | 37 | F | GBM with giant cell features | ALT | Loss | Loss | Negative |
20 | 38 | M | GBM with giant cell features | ALT | Loss | Loss | Positive |
21 | 5 | M | GBM with giant cell features | ALT | Retained | Loss | Negative |
22 | 52 | M | GBM with giant cell features | ALT | Retained | Loss | Negative |
23 | 55 | GBM with giant cell features | ALT | Retained | Loss | Positive | |
24 | 32 | M | GBM with giant cell features | ALT | Retained | Loss | Positive |
25 | 37 | F | GBM with giant cell features | ALT | Retained | Loss | Positive |
26 | 64 | F | GBM with giant cell features | Negative | Retained | Retained | Negative |
27 | 56 | F | GBM with giant cell features | Negative | Retained | Retained | Negative |
28 | 60 | F | GBM with giant cell features | Negative | Retained | Retained | Negative |
29 | 64 | M | GBM with giant cell features | Negative | Retained | Retained | Negative |
30 | 43 | F | GBM with giant cell features | Negative | Retained | Retained | Negative |
31 | 2 | F | GBM with giant cell features | Negative | Retained | Retained | Negative |
32 | 46 | M | GBM with giant cell features | Negative | Retained | Retained | Negative |
33 | 62 | F | GBM with giant cell features | Negative | Retained | Retained | Negative |
34 | 55 | F | GBM with giant cell features | Negative | N/A | Retained | Negative |
35 | 69 | M | GBM with giant cell features | Negative | N/A | Retained | Negative |
36 | 62 | F | GBM with giant cell features | Negative | Retained | Retained | Negative |
37 | 58 | M | GBM with giant cell features | Negative | Retained | Retained | Negative |
38 | 75 | F | GBM with giant cell features | Negative | Retained | Retained | Negative |
39 | 44 | M | GBM with giant cell features | Negative | Retained | Retained | Negative |
40 | 15 | F | GBM with giant cell features | Negative | Retained | Retained | Negative |
41 | 64 | M | GBM with giant cell features | Negative | Retained | Retained | Negative |
42 | 20 | M | GBM with giant cell features | Negative | Retained | Retained | Negative |
43 | 14 | M | GBM with giant cell features | Negative | Retained | Retained | Negative |
44 | 57 | M | Anaplastic astrocytoma with giant cell features | ALT | Retained | Retained | Negative |
